J&J’s Incivo Shows “Hints” Of Added Benefit, Says Germany’s IQWiG
This article was originally published in The Pink Sheet Daily
IQWiG concludes that J&J/Vertex’s new Hep C drug Incivo might be helpful in certain patient groups, but the German HTA body questions the validity of a widely-used surrogate efficacy measure.
You may also be interested in...
Germany’s IQWiG remains unconvinced about the added value offered by Intermune’s Esbriet, a decision that adds to industry concerns on assessment methodology
Lack of consistent approach in IQWiG/G-BA AMNOG-based decisions leaves industry confused about new reimbursement route.
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.